A multicenter registry study of the CD38 antibody daratumumab for the treatment of microvascular inflammation following kidney transplantation
Kidney International · 2026-11 · 110 (5) · 1262-1270
DOI: 10.1016/j.kint.2026.06.033 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Kidney International, 2026-11. Verfasst von Thomas Drasch und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, University Hospital Regensburg, Regensburg, Germany. Hauptthemen laut MEDLINE: Kidney Transplantation, Antibodies, Monoclonal, Graft Rejection, ADP-ribosyl Cyclase 1. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION: Microvascular inflammation (MVI) on kidney biopsy is associated with reduced graft survival following kidney transplantation (KT). CD38-targeting regimens, including the monoclonal antibody daratumumab, have recently emerged as a promising therapeutic strategy to counteract MVI and stabilize graft function. METHODS: Here, we retrospectively collected data on eGFR, albuminuria, kidney allograft pathology, donor specific antibodies (DSA) and donor-derived cell-free DNA (dd-cfDNA) levels from 70 KT patients both prior to and after initiation of daratumumab treatment. Safety signals were also documented. RESULTS: The study cohort consisted of 59 patients diagnosed with antibody mediated rejection (AMR) and 11 patients showing DSA- and C4d-negative MVI. Median time between transplantation and diagnosis of MVI was 36 months. Daratumumab treatment was initiated at a median of 1.6 months following diagnosis of MVI. A mixed linear model showed stabilization of eGFR from -1.6 ml/min/1.73m2/month in the year prior to the diagnosis of MVI to +0.3 ml/min/1.73m2/month after starting daratumumab. Six patients lost their graft during follow-up. Median albuminuria and dd-cfDNA levels decreased early during treatment, whereas the effect on DSA was heterogeneous. Both the number of doses and treatment duration had no measurable impact on outcome. CONCLUSIONS: Our preliminary data suggest efficacy of daratumumab in stabilizing kidney function in KT recipients with MVI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, University Hospital Regensburg, Regensburg, Germany.
- Department of Medicine III, Medical University of Vienna, Vienna, Austria.
- Department of Nephrology and Intensive Care, Charité-Universitätsmedizin Berlin, Berlin, Germany.
- Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany.
- III. Department of Medicine and Hamburg Center for Kidney Health, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- Division of Nephrology, Department of Endocrinology, Nephrology, and Rheumatology, University of Leipzig Medical Center, Leipzig, Germany.
Zitieren
APA
Drasch, T., Mayer, K. A., Böhmig, G. A., Akifova, A., Halleck, F., Budde, K., Rohlfing, D., Hinze, C., Kluger, M., Grahammer, F., Kowald, J., Baatz, S., Reuter, S., Kemmner, S., Seibt, T., Pigorsch, M., Beck, J., Bornemann-Kolatzki, K., Schütz, E., …, & Zecher, D. (2026). A multicenter registry study of the CD38 antibody daratumumab for the treatment of microvascular inflammation following kidney transplantation. Kidney International, 110(5), 1262-1270. https://doi.org/10.1016/j.kint.2026.06.033
Vancouver
Drasch T, Mayer KA, Böhmig GA, Akifova A, Halleck F, Budde K, et al. A multicenter registry study of the CD38 antibody daratumumab for the treatment of microvascular inflammation following kidney transplantation. Kidney International. 2026;110(5):1262-1270. doi:10.1016/j.kint.2026.06.033
BibTeX
@article{Drasch2026,
author = {Drasch, Thomas and Mayer, Katharina A and Böhmig, Georg A and Akifova, Aylin and Halleck, Fabian and Budde, Klemens and Rohlfing, David and Hinze, Christian and Kluger, Malte and Grahammer, Florian and Kowald, Jan and Baatz, Sebastian and Reuter, Stefan and Kemmner, Stephan and Seibt, Tobias and Pigorsch, Mareen and Beck, Julia and Bornemann-Kolatzki, Kirsten and Schütz, Ekkehard and Oellerich, Michael and Banas, Bernhard and Zecher, Daniel},
title = {A multicenter registry study of the CD38 antibody daratumumab for the treatment of microvascular inflammation following kidney transplantation},
journal = {Kidney International},
year = {2026},
volume = {110},
number = {5},
pages = {1262--1270},
doi = {10.1016/j.kint.2026.06.033}
}
EUVIMED